Current Rating and Price Target
The current rating of Pfizer by Jefferies reflects a mixed but predominantly positive assessment. Jefferies currently rates Pfizer as “Buy” and sets the price target at $32, after previously reducing it from $34 on April 14, 2025. Despite this lowered price target, long-term confidence in the corporate strategy remains intact, even though short-term setbacks such as the discontinuation of the Danuglipron study affect the credibility of management.
Context to Previous Analyst Opinions
Compared to other banks, Jefferies stands out with a positive rating. While JP Morgan Chase & Co. issued a “Neutral” rating on April 4, 2025, and Berenberg Bank advised “Hold” on March 7, 2025, DZ BANK/Goldman Sachs already recommended “Buy” on February 5, 2025. This shows that Jefferies is currently more optimistic about Pfizer’s potential than some other analyst firms.
Relevance for the German-Speaking Market
Although Pfizer may not be listed in the SDAX, the company is present as a global pharmaceutical giant with numerous locations and distribution networks in the DACH region. The current stock price of approximately €19.39–19.46 makes the price target of around €30 ambitious.
Critical Factors
Pfizer faces challenges in drug development, as recent issues have arisen with the Danuglipron study. Additionally, the consensus of sales expectations might be overly optimistic, which investors should keep an eye on. The “Buy” recommendation signals potential; however, it emphasizes the need to closely monitor clinical trials and quarterly reports.